SCHEMBL7123002

SCHEMBL7123002

Cn1c2c(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)S(=O)(=O)C(C(=O)NCc1ccc(F)cc1)C(=O)N2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
P2RX7 Q99572 2/20 0.37
MCHR1 Q99705 1/20 0.36
TRPA1 O75762 1/20 0.36
BRD4 O60885 1/20 0.34
GPR18 Q14330 1/20 0.34
MAPT P10636 2/20 0.33
RXFP1 Q9HBX9 2/20 0.33
USP2 O75604 1/20 0.33
PKM P14618 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127312 0.90 ALDH1A1 (0.49) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL7114889 0.86 ALDH1A1 (0.39) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL7063104 0.85 ALDH1A1 (0.37) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL6788504 0.82 ALDH1A1 (0.39) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL7130471 0.80 ALDH1A1 (0.37) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL7058690 0.75 GAA (0.34) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL7125681 0.74 L3MBTL1 (0.41) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL6679503 0.72 TRPA1 (0.42) ALDH1A1LMNAMEN1KMT2ATRPA1
SCHEMBL7061898 0.71 GAA (0.47) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL6679197 0.71 ALDH1A1 (0.49) ALDH1A1LMNAMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 ALDH1A1 812/4885LMNA 3842/4885MEN1 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.